Adipotide

Adipotide is unlike anything else in this catalogue, and the difference is worth stating at the outset: it was not designed to change how fat tissue behaves. It was designed to destroy the blood vessels that supply it. The compound is a peptidomimetic in two halves — a homing sequence that finds a particular target, joined to a short sequence that kills the cell it is delivered into.

The approach came from cancer research. Tumours depend on recruiting their own blood supply, and a strategy developed at MD Anderson used peptides that seek out markers on the vessels feeding a tumour and deliver a disruptive payload. The observation that made this compound possible was that the vessels supplying white adipose tissue carry a distinctive marker of their own — a protein called prohibitin.

The logic is therefore indirect and deliberately so. Fat tissue, like any tissue, needs a blood supply; remove the supply and the tissue cannot be maintained. Adipotide targets the vasculature rather than the fat cell. Whether that is a viable approach in a living animal is exactly what the research asked, and the answer turned out to be complicated.

• Tissue-specific vascular markers: The finding that blood vessels differ depending on the tissue they serve is significant on its own. It raises the possibility of addressing one tissue by its plumbing, and this compound is the main test of that idea outside oncology.

• A two-part molecular design: A homing sequence joined to a disruptive sequence is a general architecture for targeted delivery. Studying it here shows how well the approach transfers from tumours to normal tissue.

• Prohibitin as a target: Prohibitin is a protein with roles inside mitochondria and on the cell surface, and it is not fully understood. Its appearance as a vascular marker on adipose tissue is one of the more curious findings in this area.

• Why it went no further: The primate study that showed the strongest effect also found kidney changes. Understanding why a targeting strategy loses its specificity in a whole organism is a serious question for the whole field of targeted delivery.

Every tissue in the body is threaded with capillaries, and the cells lining those capillaries are not identical everywhere. They display different proteins on their surface depending on where they are, which functions as a kind of postcode. Screening methods developed in cancer research made it possible to find short peptide sequences that bind one postcode and not others.

Adipotide joins such a homing sequence to a second, very different one. The second part is designed to be harmless outside a cell and disruptive inside it: on reaching the interior it disturbs mitochondrial membranes, and the cell initiates its own controlled shutdown. Combining the two is meant to produce a molecule that is inert almost everywhere and lethal only where it docks.

Applied to fat tissue, the intended chain of events is that vessels feeding white adipose tissue are eliminated, the tissue loses its supply, and it cannot be sustained. A rhesus monkey study reported substantial reductions in body weight consistent with that. It also reported changes in kidney function — and since the kidney is one of the most densely vascularised organs in the body, that finding raises the question of whether the postcode was ever as specific as the design assumed.

The published record is small, high quality and clear about its own limits. The primate work appeared in a leading peer-reviewed journal in 2011 and reported both the weight reduction and the renal findings. Rodent studies preceded it with similar results.

There is no approved use and no clinical data; human trials were discussed and did not proceed. It is supplied for laboratory research only. As a research compound it is the principal tool for a distinctive idea — addressing a tissue through the blood vessels that supply it — and the primate study reports both the weight reduction and the renal findings.

Nothing else in this category works this way, which is the most useful thing to say about it. AOD-9604 and 5-Amino-1MQ act on metabolic pathways inside cells that remain alive and functioning; this compound is studied for removing tissue rather than for changing how it behaves.

That distinction matters when reading any comparison between them. A metabolic compound and a targeted vascular agent are not alternatives to one another, and evidence about one says nothing about the other.